|
TCRT | Alaunos Therapeutics, Inc. |
|
|
TCRT | Alaunos Therapeutics, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.00 |
| Leverage | 24.73% |
| Market Cap | $ 830.2m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -4.0m |
| Margin | -4682.89% |
Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring, developing and commercializing a portfolio of immuno-oncology therapies to treat cancer patients. The company is headquartered in Houston, Texas.